Physician profile
Kenneth Surkin
NPI 1295050227
$1,170.97
in general payments reported to CMS, 2019-2025
10 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.01 · 2020: $294 · 2021: $224 · 2022: $266 · 2023: $59.13 · 2024: $60.52 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $389.72 | 2019-2022 | |
| Pfizer INC. | $314.56 | 2020-2025 | |
| Mylan Specialty L.P. | $127.81 | 2020 | |
| Abbvie INC. | $93.84 | 2021-2024 | Teflaro |
| E.R. Squibb & Sons, L.L.C. | $70.32 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $58.47 | 2019-2023 | |
| Angiodynamics, INC. | $46.61 | 2024-2025 | Angiovac |
| Astrazeneca Pharmaceuticals LP | $29.70 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.33 | 2025 | Ultomiris |
| Novo Nordisk INC | $17.61 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Surkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.